Opinion|Videos|July 15, 2024
Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population
Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss the data for 2L treatment with CAR T-cell therapy for patients who are transplant-ineligible.
- Do the defining characteristics of transplant-ineligible used in the following studies reflect which patients are considered transplant-ineligible in the real world?
- ALYCANTE- Phase 2 trial.
- PILOT – Phase 2 trial.
- What are some key takeaways from the results of these two studies?
Advertisement
Related to this article
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
5